Increased Serum Cu/Zn SOD in Individuals with Clinical Depression Normalizes After Zinc and Anti-oxidant Therapy

A.J. Russo

Research Director, Health Research Institute/Pfeiffer Treatment Center, 4575 Weaver Parkway, Warrenville, Illinois 60555. Corresponding author email: ajrusso@hriptc.org

Abstract

Aim: To assess serum Cu/Zn SOD (Superoxide Dismutase) concentration in individuals with clinical depression.

Subjects and methods: Serum from 36 individuals diagnosed with clinical depression and 18 healthy controls were tested for Cu/Zn SOD serum concentration using ELISAs.

Results: Serum Cu/Zn SOD levels of depressed individuals (both with and without secondary anxiety) were significantly higher than age and gender similar controls. We also found that, post anti-oxidant therapy, Cu/Zn SOD levels normalized to the level of normal healthy controls.

Discussion: These results suggest an association between Cu/Zn SOD serum levels and clinical depression.

Keywords: depression, Cu/Zn SOD, super oxide dismutase, oxidative stress
Introduction

Clinical depression is a considerable public health problem. Approximately 32 to 35 million adults in the United States have experienced depression at some point in their life and approximately 13 million adults have experienced depression within the past year. Clinical depression is also a considerable medical problem as those with major depressive disorder (MDD) are at increased risk for serious medical illness, including cardiovascular disease, diabetes, cancer, and stroke. This risk is often independent of traditional risk factors, suggesting that depression may function as a causal factor in the pathogenesis of multiple diseases. To understand the pathophysiological effects of depression, we examined one of the biologic mechanisms common to multiple diseases: oxidative damage to DNA.

Oxidative damage results from biochemical interactions between reactive oxygen species (ROS) and target biomolecules. ROS can damage nucleic acids, lipids, and proteins, and figures prominently in the etiology and progression of numerous cancers as well as coronary and carotid atherosclerosis.

Oxidative stress, occurring as a consequence of imbalance between the formation of free oxygen radicals and inactivation of these species by antioxidant defense system, is capable of causing damage to various cellular and extracellular constituents. The deleterious effects of increased oxidative stress are termed oxidative damage. These effects generally appear after exposure to a relatively high concentration of reactive oxygen species (ROS) and/or a decrease in antioxidant (AO) defense system against ROS.

In vivo, oxygen radicals are produced as byproducts of normal oxidative metabolism. Hence, activated cells with increased metabolism produce more oxygen radicals. It has long been known that control of the intracellular redox environment is vital for proper cellular function. To protect themselves from the constant oxidative challenge, cells have developed defense mechanisms that ensure a proper balance between pro- and antioxidant molecules.

Cu/Zn superoxide dismutase (SOD-1) is a key enzyme in the dismutation of superoxide radicals resulting from cellular oxidative metabolism, converting them into hydrogen peroxide, and, as a result, serves a key antioxidant role. In fact, mice lacking SOD die several days after birth, amidst massive oxidative stress. Copper, and zinc participate in SOD enzymatic mechanisms that protect against free radicals and therefore serve an important adjunct role in oxidative balance.

Our study was designed to determine Cu/Zn SOD serum levels in clinically depressed individuals and test the hypothesis that this oxidative stress marker is increased in depressed individuals. This oxidative imbalance may lead to depressive symptoms.

Materials and Methods

ELISA to measure serum Cu/Zn SOD (bender systems)

All reagents and specimens were equilibrated to room temperature before the assay was performed. A 1:51 dilution of the patient samples was prepared by mixing 10 µl of the patient’s sera with 0.5 ml of Serum Diluent. One hundred microliters of calibrators (0.08–2.5 ng/ml Cu/Zn SOD), serum diluent alone, and diluted patient samples were added to the appropriate microwells of a microculture plate (each well contained affinity purified polyclonal IgG to Cu/Zn SOD). Wells were incubated for 60 minutes (± 5 min) at room temperature, then washed 4× with wash buffer. One hundred microliters of prediluter anti-human Cu/Zn SOD IgG conjugated with HRP was added to all microwells, incubated for 30 minutes (± 5 min) at room temperature, then wash 4× with wash buffer. One hundred microliters of enzyme substrate was added to each microwell. After approximately 30 minutes at room temperature, the reaction was stopped by adding 50 µl of 1M sulfuric acid, then the wells were read at 450 nm with an ELISA reader (BioRad Laboratories, Inc., Hercules, CA, USA).

Subjects

Experimental and controls

Serum from individuals with diagnosed clinical depression (n = 26; 10 male; mean age 35.2 years) and controls (n = 19; 5 male; mean age 41.7 years) was obtained from patients presenting at the Health Research Institute/Pfeiffer Treatment Center Warenville, II.* Patients were chosen for this study by presenting to the Pfeiffer Treatment Center for depression and agreeing to be involved in research at the Center. Most of these

---

*The Pfeiffer Treatment Center is a comprehensive research and treatment center, specializing in the care of with neurological disorders, including Depression.
Increased serum Cu/Zn SOD in depression

Nutrition and Metabolic Insights 2010:3

individuals were diagnosed using The Hamilton Rating Scale for Depression before presenting at the Pfeiffer Treatment Center. Healthy controls included individuals with no documented mental illness, recruited from the community and agreeing to the research. The sample size was determined by the number of depression patients and controls available at the time of the study.

Cases and controls were age and gender similar (see above). Smokers and individuals taking medications which might affect oxidative stress, such as steroids, statins and indole-derived drugs, were eliminated from the study.

Anti-oxidant Therapy

Individuals in this study who presented to the Pfeiffer Treatment Center with depression were tested for anti-oxidant levels. Based on deficiencies, they were then prescribed the appropriate dosage of anti-oxidant. Pre-therapy patients represent those who were tested when they first presented and were not previously taking any anti-oxidants. Post-Therapy patients received anti-oxidant therapy, including zinc supplementation if necessary, for a minimum of 8 weeks.

Serum/Plasma

All experimental and control serums were drawn using venipuncture then treated in an identical fashion—frozen at −70°C immediately after collection and cell/serum separation, then stored at −70°C until thawed for use in ELISAs.

Statistics

Inferential statistics were derived from unpaired t-tests.

Results

Serum from 36 individuals diagnosed with clinical depression and 18 age and gender matched controls was tested for Cu/Zn SOD plasma concentration using an ELISA (described above). Each assay was repeated two or more times, with multiple wells for each serum in each assay. Results of a typical assay with assay controls and depressed and control individuals are shown in Figures 1 and 2, respectively.

Serum Cu/Zn SOD levels of depressed individuals were significantly higher than all non-depressed controls ($P < 0.0025$) (Table 1). Although Cu/Zn SOD levels were higher in depressed individuals with secondary anxiety, when compared to depressed individuals without anxiety, this difference was not significant.

Medical records were available for 28 of the 36 depressed individuals in this study. Cu/Zn SOD levels in 18 of these same individuals after anti-oxidant therapy was significantly lower than 10 who presented with depression for the first time (before therapy) ($P = 0.037$) (Table 2) and Cu/Zn SOD levels normalized post therapy when compared to controls ($P = 0.305$) (Table 4).

Perceived severity of depression (scale of 0–5 (5 being the most severe depression)) was asked of 21 of the 36 depressed individuals in this study. There was a significantly lower level of perceived depression post anti-oxidant therapy ($P = 0.0031$) (Table 3).

Discussion

Oxidative stress has been implicated in the pathogenesis of a diverse group of disease states,
Depressed individuals and controls

Figure 2. In a typical ELISA, plasma from 3 individuals diagnosed with clinical depression and three normal (neuro-typical) age/gender matched individuals was tested for the Cu/Zn SOD concentration. Cu/Zn SOD concentration is significantly higher in the depressed individuals.

Table 1. Cu/Zn SOD plasma levels in depressed individuals are significantly higher than in normal controls.

|          | Depression | Normal controls |
|----------|------------|-----------------|
| Mean     | 0.695      | 0.326           |
| SD       | 0.479      | 0.149           |
| SEM      | 0.080      | 0.035           |
| N        | 36         | 18              |

Note: The two-tailed P value equals 0.0025. \( t = 3.1769; \) df = 52; standard error of difference = 0.116.

Table 2. Individuals with clinical depression had significantly lower serum Cu/Zn SOD concentration (ng/ml) after antioxidant therapy.

|          | Cu/Zn SOD before therapy | Cu/Zn SOD after therapy |
|----------|--------------------------|-------------------------|
| Mean     | 0.751                    | 0.437                   |
| SD       | 0.331                    | 0.412                   |
| SEM      | 0.078                    | 0.130                   |
| N        | 18                       | 10                      |

Note: The two-tailed P value equals 0.0368. \( t = 2.2018; \) df = 26; standard error of difference = 0.142.

and, because the brain has comparatively greater vulnerability to oxidative damage, may be a common pathogenic mechanism underlying many major psychiatric disorders.

This study represents an attempt to assess levels of the oxidative damage expressed by Cu/Zn SOD levels in the plasma of clinically depressed, but otherwise healthy adults. As our results demonstrate, compared with matched control subjects, those with clinical depression show significantly higher serum levels of Cu/Zn SOD.

Other studies have shown positive correlations between levels of 8-OhdG, negative mood, as measured by Profile of Mood States, perceived workload, psychological distress and the perceived impossibility of alleviating distress and severe depression as measured by the General Health Questionnaire.

Clinical depression associated with increased oxidative damage may represent a common pathophysiological mechanism, whereby these patients become vulnerable to multiple comorbid medical illnesses.

Depression is associated with an activation of innate immune responses, inflammation and heightened vulnerability to latent infection. Activated phagocytes are significant sources of ROS and produce superoxide, hydrogen peroxide, nitric oxide, and peroxynitrite as part of the cytotoxic host response against invading pathogens.

Depression may contribute to oxidative damage through an increase in the production of reactive oxygen species (ROS). ROS can be antimicrobial; they damage lipid membranes and protein structures, thus destroying antigen-bearing cells. Oxidative damage is not limited to microbial targets, however, and extensive host tissue damage may result. ROS from activated phagocytes can damage DNA bases and induce strand breaks in neighboring cells, leading some to argue that the hydroxyl radicals and peroxynitrite formed during inflammation are the greatest contributors to the oxidation of DNA.
Clinical relevance of increased oxidative damage, evidenced by clinically depressed individuals, is currently unknown, and future studies should appropriately address this deficit. Our data are consistent with the hypothesis that oxidative damage is a potential common pathophysiological mechanism underlying multiple co-morbid conditions in depressed people. Future studies should include measurement of multiple oxidative damage markers to different macromolecules, associated dietary deficiencies associated with these markers, associated severity of depression, and should address whether depression remission remediates underlying oxidative damage.

Acknowledgements
I’d like to thank Scott Filer, Executive Director, and Allen Lewis, Medical Director of The Pfeiffer Treatment Center for their support and help in this research and manuscript preparation.

I’d also like to thanks Laurie Myers and Kyle Andrews for their technical assistance.

References
1. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53:849–57.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.
3. Lett HS, Blumenthal JA, Babayak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305–15.
4. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54:227–40.
5. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.
6. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317–29.
7. Eaton WW. Epidemiologic evidence on the comorbidity of depression and diabetes. J Psychosom Res. 2002;53:903–6.
8. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19:1097–102.
9. Penninx BWJ, Guralnik JM, Pahor M, et al. Chronically depressed mood and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001;32:1979–83.
10. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res. 2001;477:7–21.
11. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54:269–82.
12. Larson SL, Owens PL, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke: a meta-analysis of 13 studies. Circulation. 2003;108:1447–50.
13. Floyd RA. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis. 1990;11:1447–50.
14. Marnett LJ. Oxidative stress and DNA damage. Trends Cardiovasc Med. 2003;13:270–5.
15. Botto N, Masetti S, Petrozzi L, et al. Elevated levels of oxidative DNA damage in patients with coronary artery disease. Coron Artery Dis. 2002;13:269–74.
16. Martinet W, Knaapen MWM, De Meyer GRY, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002;106:927–32.

Table 3. When individuals with depression were asked to assess their levels of depression (0–5; 5 being the most severe), depression severity was significantly lower after therapy.

| Depression severity | Depression severity |
|---------------------|---------------------|
| no therapy          | after therapy       |
| Mean 4.154          | 2.688               |
| SD 0.718            | 1.28                |
| SEM 0.199           | 0.453               |
| N 13                | 8                   |

Note: The two-tailed *P* value equals 0.0031. *t* = 3.3846; df = 19; standard error of difference = 0.433.

Table 4. Cu/Zn SOD levels normalized in depressed individuals after anti-oxidant therapy and zinc supplementtion.

| Cu/Zn SOD after | Cu/Zn SOD controls |
|-----------------|---------------------|
| therapy         |                     |
| Mean 0.437      | 0.326               |
| SD 0.412        | 0.149               |
| SEM 0.130       | 0.035               |
| N 10            | 18                  |

Note: The two-tailed *P* value equals 0.3049. *t* = 1.0466; df = 26; standard error of difference = 0.107.
Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:
- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

http://www.la-press.com